Shared and differing treatment goals in major depressive disorder

Professor Roger McIntyre sat down at ECNP 2022 and discussed how essential shared prescriber-patient therapeutic objectives are prior to antidepressant treatment choice and initiation for patients with major depressive disorder (MDD). Patients and prescribers may differ in how they rank the order of importance of these objectives, with prescribers lending more weight to symptom improvement and patients to functionality. This needs to be taken into consideration when deciding which antidepressant treatment to prescribe. Partial response to treatment is common in MDD and can, discussed Prof McIntyre, be ascertained as soon as 2−3 weeks following treatment initiation. Following dose optimisation, further partial response can then be determined after an additional 1−2 weeks and an alternative treatment strategy can be then utilised if needed.

You are leaving Progress in Mind
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country